Differences and Similarities Between the EULAR/ASAS-EULAR and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706
Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589
Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis: Analysis of Pooled Data from Two Phase 3 Studies
Arthritis Res Ther. 2023 22;25(1):153 doi: 10.1186/s13075-023-03108-5
Post-hoc analysis of two tofacitinib phase three studies concludes that tofacitinib treatment resulted in improvements in enthesitis in patients with PsA, regardless of baseline location or severity.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519
Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005
Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00576-8 Epub ahead of print
The data gathered in this post-marketing surveillance study aligned with the previously established safety profile of tofacitinib, and reports were found to have consistent safety profiles in the treatment of both patient with PsA and RA. However, the results of this study should be interpreted considering the limitations of post-marketing surveillance studies.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 3-year Results from the Open-Label Extension of the Randomised Controlled Phase 3 SELECT-PsA 2 Study
Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/8l7bbk. Epub ahead of print
Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.
The 2023 Pipeline of Disease-Modifying Antirheumatic Drugs (DMARDs) in Clinical Development for Spondyloarthritis (including psoriatic arthritis): a Systematic Review of Trials
RMD Open. 2023;9(3):e003279 doi 10.1136/rmdopen-2023-003279 https://pubmed.ncbi.nlm.nih.gov/37507210/
This systematic review identified DMARDs evaluated for axSpA and PsA, distinguishing between csDMARDs, tsDMARDs, and bDMARDs. The review pinpointed twenty-six distinct targeted therapies currently in clinical development; 18 therapies for axSpA and 15 therapies for PsA.
Improvement in Patient-reported Outcomes and Work Productivity Following 3-year Ustekinumab or Tumour Necrosis Factor Inhibitor Treatment in Patients with Psoriatic Arthritis: Results from the PsABio Real-world Study
Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y
Results from the 3-year PsABio study demonstrated that, generally, ustekinumab and TNFi treatment led to an improvement in PROs. In coming to this conclusion, researchers aimed to evaluate the real-world effect of ustekinumab or a TNFi on PRO and their association with effectiveness endpoints in PsA patients over 3 years.
Apremilast Long‑Term Safety Up to 5 Years from 15 Pooled Randomized, placebo‑Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
Am J Clin Dermatol. 2023 Jun 14:1–12 doi: 10.1007/s40257-023-00783-7 Epub ahead of print
This study confirms the safety of long-term apremilast use in patients with plaque PsO, active PsA, or oral ulcers associated with Behçet’s syndrome. In coming to this conclusion, investigators conducted a pooled analysis of apremilast data from 15 clinical studies with open-label extension phases, focusing on long-term safety.